TWST: יחס שווי פעילות לרווח לפני ריבית, מסים ופחת twistbioscience.com

Twist Bioscience (TWST) leads the synthetic biology sector by producing DNA on silicon chips for bioengineering. The EV/EBITDA metric, accounting for debt and amortization, reflects the current market phase, where the value 0.00 determines this level. Despite rapid ARR growth, significant cash burn and patent disputes hinder the company, constraining its path to net profitability.

DNA synthesis on silicon platforms requires significant capital expenditures, which is why the EV/EBITDA ratio allows for an assessment of the efficiency of Twist Bioscience (TWST) robotic factories without accounting for tax burdens or debt obligations. By analyzing the historical EV/EBITDA multiple, an investor can determine the real value of Twist Bioscience (TWST) assets, eliminating market noise and the risk of overpaying for temporary growth.